Quoin Pharmaceuticals CFO Lawlor buys $49,990 in company stock

Sally Bridget Lawlor, Chief Financial Officer of Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX), recently acquired company stock totaling $49,990. The transaction, reported on August 31, 2026, involved the purchase of American Depositary Shares (ADSs) as part of an issuer’s private placement.

Ms. Lawlor purchased 10,244 ADSs at a price of $4.88 per ADS. Following this acquisition, her direct beneficial ownership in Quoin Pharmaceuticals stands at 10,684 ADSs. Each ADS represents thirty-five ordinary shares of the Issuer. The timing of the purchase appears notable, as the stock has since rallied 25.68% over the past week to trade at $6.51, though InvestingPro analysis suggests the stock is currently overvalued relative to its Fair Value. The company maintains a market capitalization of $13.07 million and holds more cash than debt on its balance sheet, according to InvestingPro Tips—part of 11 additional insights available to subscribers.

In the same private placement, Ms. Lawlor also acquired 5,122 ordinary warrants, which were issued at a combined purchase price of $4.88 with the ADSs. These warrants, exercisable immediately, grant the right to buy 5,122 ADSs at an exercise price of $6.1 per ADS. The warrants are set to expire on the earlier of five years from issuance or 30 days after the company publicly announces that the primary endpoint has been met in its CL-QRX003-004 clinical trial for Netherton Syndrome.

In other recent news, Quoin Pharmaceuticals Ltd. has made significant strides with its QRX003 treatment. The company has established a wholly-owned subsidiary in Japan to support the potential commercialization of QRX003 for Netherton Syndrome, following the grant of Orphan Drug Designation by Japan’s Ministry of Health, Labour and Welfare. This move will enable Quoin Pharmaceuticals to engage more effectively with Japanese regulators, clinicians, and patient advocacy organizations. Additionally, Quoin Pharmaceuticals has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for QRX003 to treat Peeling Skin Syndrome, a rare skin disorder with no current treatment. This submission marks the first IND application for this condition, with plans to initiate a Phase 2 clinical study in the second half of 2026, pending FDA review. These developments highlight the company’s ongoing efforts to advance its treatment options for rare skin disorders.